The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey: Patients' experience with allergen immunotherapy

David P. Skoner, Michael S. Blaiss, Mark S. Dykewicz, Nancy Smith, Bryan Leatherman, Leonard Bielory, Nicole Walstein, Timothy J. Craig, Felicia Allen-Ramey

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Allergen immunotherapy (AIT) is used for the treatment of allergic rhinoconjunctivitis as a subcutaneous injection (subcutaneous immunotherapy [SCIT]). Extracts used for SCIT are also used off-label to formulate a liquid delivered as sublingual drops (sublingual immunotherapy [SLIT]). This study was designed to survey patients' experiences and beliefs regarding SCIT and SLIT. People who had ever been diagnosed with nasal and/or ocular allergies were identified in a 2012 telephone survey of U.S. households. Respondents were asked questions about their or their child's use of SCIT and SLIT and their beliefs about AIT. Of 2765 respondents, 46.5% had ever heard of AIT and 22.7% had ever initiated it: 20.9% with SCIT and 1.8% with SLIT (p < 0.0001). The most frequently cited reason for beginning AIT was that symptoms were unresolved with other medications (SCIT, 32.1%; SLIT, 14.0%). Some or full symptom relief was reported by 74.9% of respondents treated with SCIT and 66.0% of those treated with SLIT (p = 0.17 for SCIT versus SLIT). Approximately one-third of respondents who had ever heard of or had been treated with AIT said "don't know" when asked if immunotherapy controls allergy symptoms for years (33.6%), is a very safe treatment (29.3%), or can cure allergy symptoms (27.5%). Effective relief of allergy symptoms was cited most often as the primary benefit of SCIT (37.8%) and convenience was the primary benefit of SLIT (14%). Only one-fifth of respondents had ever been treated with AIT, largely with SCIT. More than one-half of respondents had never heard of AIT and respondents' beliefs indicated a need for educational efforts.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalAllergy and Asthma Proceedings
Volume35
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunologic Desensitization
Sublingual Immunotherapy
Immunotherapy
Hypersensitivity
Surveys and Questionnaires
Subcutaneous Injections
Nose
Telephone

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Skoner, D. P., Blaiss, M. S., Dykewicz, M. S., Smith, N., Leatherman, B., Bielory, L., ... Allen-Ramey, F. (2014). The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey: Patients' experience with allergen immunotherapy. Allergy and Asthma Proceedings, 35(3), 219-226. https://doi.org/10.2500/aap.2014.35.3752
Skoner, David P. ; Blaiss, Michael S. ; Dykewicz, Mark S. ; Smith, Nancy ; Leatherman, Bryan ; Bielory, Leonard ; Walstein, Nicole ; Craig, Timothy J. ; Allen-Ramey, Felicia. / The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey : Patients' experience with allergen immunotherapy. In: Allergy and Asthma Proceedings. 2014 ; Vol. 35, No. 3. pp. 219-226.
@article{640a08007dad46c4a74e3d5dcb863ee0,
title = "The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey: Patients' experience with allergen immunotherapy",
abstract = "Allergen immunotherapy (AIT) is used for the treatment of allergic rhinoconjunctivitis as a subcutaneous injection (subcutaneous immunotherapy [SCIT]). Extracts used for SCIT are also used off-label to formulate a liquid delivered as sublingual drops (sublingual immunotherapy [SLIT]). This study was designed to survey patients' experiences and beliefs regarding SCIT and SLIT. People who had ever been diagnosed with nasal and/or ocular allergies were identified in a 2012 telephone survey of U.S. households. Respondents were asked questions about their or their child's use of SCIT and SLIT and their beliefs about AIT. Of 2765 respondents, 46.5{\%} had ever heard of AIT and 22.7{\%} had ever initiated it: 20.9{\%} with SCIT and 1.8{\%} with SLIT (p < 0.0001). The most frequently cited reason for beginning AIT was that symptoms were unresolved with other medications (SCIT, 32.1{\%}; SLIT, 14.0{\%}). Some or full symptom relief was reported by 74.9{\%} of respondents treated with SCIT and 66.0{\%} of those treated with SLIT (p = 0.17 for SCIT versus SLIT). Approximately one-third of respondents who had ever heard of or had been treated with AIT said {"}don't know{"} when asked if immunotherapy controls allergy symptoms for years (33.6{\%}), is a very safe treatment (29.3{\%}), or can cure allergy symptoms (27.5{\%}). Effective relief of allergy symptoms was cited most often as the primary benefit of SCIT (37.8{\%}) and convenience was the primary benefit of SLIT (14{\%}). Only one-fifth of respondents had ever been treated with AIT, largely with SCIT. More than one-half of respondents had never heard of AIT and respondents' beliefs indicated a need for educational efforts.",
author = "Skoner, {David P.} and Blaiss, {Michael S.} and Dykewicz, {Mark S.} and Nancy Smith and Bryan Leatherman and Leonard Bielory and Nicole Walstein and Craig, {Timothy J.} and Felicia Allen-Ramey",
year = "2014",
month = "1",
day = "1",
doi = "10.2500/aap.2014.35.3752",
language = "English (US)",
volume = "35",
pages = "219--226",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "3",

}

Skoner, DP, Blaiss, MS, Dykewicz, MS, Smith, N, Leatherman, B, Bielory, L, Walstein, N, Craig, TJ & Allen-Ramey, F 2014, 'The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey: Patients' experience with allergen immunotherapy', Allergy and Asthma Proceedings, vol. 35, no. 3, pp. 219-226. https://doi.org/10.2500/aap.2014.35.3752

The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey : Patients' experience with allergen immunotherapy. / Skoner, David P.; Blaiss, Michael S.; Dykewicz, Mark S.; Smith, Nancy; Leatherman, Bryan; Bielory, Leonard; Walstein, Nicole; Craig, Timothy J.; Allen-Ramey, Felicia.

In: Allergy and Asthma Proceedings, Vol. 35, No. 3, 01.01.2014, p. 219-226.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey

T2 - Patients' experience with allergen immunotherapy

AU - Skoner, David P.

AU - Blaiss, Michael S.

AU - Dykewicz, Mark S.

AU - Smith, Nancy

AU - Leatherman, Bryan

AU - Bielory, Leonard

AU - Walstein, Nicole

AU - Craig, Timothy J.

AU - Allen-Ramey, Felicia

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Allergen immunotherapy (AIT) is used for the treatment of allergic rhinoconjunctivitis as a subcutaneous injection (subcutaneous immunotherapy [SCIT]). Extracts used for SCIT are also used off-label to formulate a liquid delivered as sublingual drops (sublingual immunotherapy [SLIT]). This study was designed to survey patients' experiences and beliefs regarding SCIT and SLIT. People who had ever been diagnosed with nasal and/or ocular allergies were identified in a 2012 telephone survey of U.S. households. Respondents were asked questions about their or their child's use of SCIT and SLIT and their beliefs about AIT. Of 2765 respondents, 46.5% had ever heard of AIT and 22.7% had ever initiated it: 20.9% with SCIT and 1.8% with SLIT (p < 0.0001). The most frequently cited reason for beginning AIT was that symptoms were unresolved with other medications (SCIT, 32.1%; SLIT, 14.0%). Some or full symptom relief was reported by 74.9% of respondents treated with SCIT and 66.0% of those treated with SLIT (p = 0.17 for SCIT versus SLIT). Approximately one-third of respondents who had ever heard of or had been treated with AIT said "don't know" when asked if immunotherapy controls allergy symptoms for years (33.6%), is a very safe treatment (29.3%), or can cure allergy symptoms (27.5%). Effective relief of allergy symptoms was cited most often as the primary benefit of SCIT (37.8%) and convenience was the primary benefit of SLIT (14%). Only one-fifth of respondents had ever been treated with AIT, largely with SCIT. More than one-half of respondents had never heard of AIT and respondents' beliefs indicated a need for educational efforts.

AB - Allergen immunotherapy (AIT) is used for the treatment of allergic rhinoconjunctivitis as a subcutaneous injection (subcutaneous immunotherapy [SCIT]). Extracts used for SCIT are also used off-label to formulate a liquid delivered as sublingual drops (sublingual immunotherapy [SLIT]). This study was designed to survey patients' experiences and beliefs regarding SCIT and SLIT. People who had ever been diagnosed with nasal and/or ocular allergies were identified in a 2012 telephone survey of U.S. households. Respondents were asked questions about their or their child's use of SCIT and SLIT and their beliefs about AIT. Of 2765 respondents, 46.5% had ever heard of AIT and 22.7% had ever initiated it: 20.9% with SCIT and 1.8% with SLIT (p < 0.0001). The most frequently cited reason for beginning AIT was that symptoms were unresolved with other medications (SCIT, 32.1%; SLIT, 14.0%). Some or full symptom relief was reported by 74.9% of respondents treated with SCIT and 66.0% of those treated with SLIT (p = 0.17 for SCIT versus SLIT). Approximately one-third of respondents who had ever heard of or had been treated with AIT said "don't know" when asked if immunotherapy controls allergy symptoms for years (33.6%), is a very safe treatment (29.3%), or can cure allergy symptoms (27.5%). Effective relief of allergy symptoms was cited most often as the primary benefit of SCIT (37.8%) and convenience was the primary benefit of SLIT (14%). Only one-fifth of respondents had ever been treated with AIT, largely with SCIT. More than one-half of respondents had never heard of AIT and respondents' beliefs indicated a need for educational efforts.

UR - http://www.scopus.com/inward/record.url?scp=84899868307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899868307&partnerID=8YFLogxK

U2 - 10.2500/aap.2014.35.3752

DO - 10.2500/aap.2014.35.3752

M3 - Article

C2 - 24801464

AN - SCOPUS:84899868307

VL - 35

SP - 219

EP - 226

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 3

ER -